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Abstract
The analytical performances of needle trapmicro-extraction (NTME) coupledwith gas chromato-
graphy-tandemmass spectrometry were evaluated by analyzing amixture of twenty-two representa-
tive breath volatile organic compounds (VOCs) belonging to different chemical classes (i.e.
hydrocarbons, ketones, aldehydes, aromatics and sulfurs). NTME is an emerging technique that
guarantees detection limits in the pptv range by pre-concentrating low volumes of sample, and it is
particularly suitable for breath analysis. Formost VOCs, detection limits between 20 and 500 pptv
were obtained by pre-concentrating 25ml of a humidified standard gasmixture at aflow rate of
15mlmin−1. For all compounds, inter- and intra-day precisions were always below 15%, confirming
the reliability of themethod. The procedurewas successfully applied to the analysis of exhaled breath
samples collected from forty heart failure (HF) patients during their stay in theUniversityHospital of
Pisa. Themajority of patients (about 80%) showed a significant decrease of breath acetone levels (a
factor of 3 or higher) at discharge compared to admission (acute phase) in correspondence to the
improved clinical conditions during hospitalization, thusmaking this compound eligible as a
biomarker ofHF exacerbation.
1. Introduction
Needle trap micro-extraction (NTME) coupled with
gas chromatography-mass spectrometry (GC-MS)
represents an emerging and promising technique that
guarantees detection limits in the pptv range by pre-
concentrating a volume of breath less than 50 ml [1]. A
needle trap device (NTD) consists of a stainless-steel
needle (22 or 23 gauge) packed with few milligrams of
different types of stationary phases. Such devices,
introduced for the first time in the late nineties [2],
allows combining the sample collection and the
analyte pre-concentration in a single step requiring
less than 3 min to be accomplished. The technique has
been already applied to environmental [3–5] and
clinical [1, 6] studies, even it is still evolving. Analyses
by NTDs are technically easy and straightforward,
since the sample desorption occurs directly into a
standard GC injector without the necessity of an
additional thermal desorption unit [7]. The simplest
method to transfer the adsorbed analytes to the
capillary column is the expansive flow technique,
which exploits the gas flow generated by the thermal
expansion of air inside the needle [7]. When working
with water-saturated samples like breath, the deso-
rption efficiency is enhanced by the additional flow
generated from the expansion of the water vapor
during the desorption step [1, 6, 8]. As recently
reported [8], the presence of water does not represent a
significant problem for the GC column and for theMS











Original content from this
workmay be used under
the terms of the Creative
CommonsAttribution 3.0
licence.
Any further distribution of
this workmustmaintain
attribution to the
author(s) and the title of
thework, journal citation
andDOI.
© 2017 IOPPublishing Ltd
Breath analysis by NTD can be a potential tool to
diagnose diseases at an early stage or to monitor their
evolution, especially in the case of chronic diseases
such as heart failure (HF). The composition of the
breath depends on several factors whose relative effect
is very difficult to quantify [10, 11]. To improve the
interpretation of the experimental findings, a more in-
depth knowledge of the metabolic processes and their
relationship with the presence of volatile organic com-
pounds (VOCs) in the breath samples is needed. Cur-
rently, in our opinion, the most useful approach for
breath monitoring analysis is to focus on single sub-
jects acting as their own control.
HF is a complex clinical syndrome caused by a
wide range of cardiovascular disorders leading to
structural or functional abnormalities of the heart, and
it represents a main cause of mortality and poor qual-
ity of life in the western societies [12]. According to the
EuropeanHeart Failure Association, 26million people
experience HF globally and 3.6 million people are
diagnosed with HF every year. Prevalence is expected
to increase in the coming years, so that more than 8
million people aged over 18 are expected in 2030 [13].
The main HF symptoms are fatigue and dyspnea,
which limit exercise tolerance, and fluid retention that
may lead to pulmonary and/or splanchnic congestion
and/or peripheral edema. HF is a condition very often
associated with poor prognosis and frequent hospital
admissions [12]. Nowadays, the common clinical
approaches used to diagnose and monitor HF are
based on (i) clinical history and physical examination,
to provide information about familial cardiac diseases
and severity degree, (ii) electrolyte (e.g. sodium and
potassium), albumin and creatinine determination in
blood and (iii) transthoracic Doppler 2D echocardio-
graphy [9]. Natriuretic peptides such as B-type or
N-terminal pro-B-type natriuretic peptides have been
intensively studied to monitor HF [14, 15]. Moreover,
there is an increasing interest for the identification of
biomarkers for this pathological condition, possibly in
easy-to-collect biological fluids by minimally invasive
procedures, to improve early identification of relapses
that would reduce hospital admissions and improve
prognosis, especially for stableHFpatients [16].
Breath analysis is extraordinarily appealing for an
effective, easy, painless and non-invasive monitoring
of HF patients because the chemical composition of
exhaled breath reflects in real time the physiological
and pathophysiological processes occurring in the
body [10, 17, 18]. Generally, the analysis of VOCs in
exhaled breath is carried out off-line by (i) collecting
the sample in sampling bags (e.g. Tedlar [19] or Nalo-
phan [20]), (ii) pre-concentrating the compounds of
interest using solid phase extraction [21] or solid phase
micro-extraction (SPME) [22] and, finally, (iii) analyz-
ing the sample by thermal desorption coupled to GC-
MS. The real-time measurement of carbon dioxide by
infrared sensors can allow the selection of specific
breath fractions and improve the representativeness of
samples [23, 24]. In addition, analytical approaches
(e.g. selected ion flow tube MS and proton transfer
reaction MS) based on the injection of breath samples
directly into the instrument are also available. How-
ever, the cost of the instrumentation and the uncertain
identification of analytes (e.g. isobaric compounds)
are the main drawbacks of these procedures [25, 26],
making the off-linemethods themost commonly used
in thisfield.
In the present work, the analytical performances of
triple-bed NTDs, packed with 1 cm of each Divi-
nylbenzene, Carbopack X and Carboxen 1000, were
evaluated by analyzing a humidified standard gaseous
mixture of twenty-two VOCs. The selected com-
pounds are representative of breath composition
belonging to different chemical classes (i.e. hydro-
carbons, ketones, aldehydes, aromatics and sulfurs)
[27, 28]. Finally, the proposed NTME-GC-MS/MS
procedure was successfully applied to the determina-
tion of the chemical composition of exhaled breath
samples collected from 40 patients suffering from HF




Ethanol, 2-propanol, 1-propanol, 1-butanol, butanal,
pentanal, hexanal, heptanal, benzaldehyde,
2-butanone, 2-pentanone, 2-hexanone, 2-heptanone
and 4-heptanone were from AccuStandard, Inc. Che-
mical Reference Standard (USA), whereas isoprene,
acetone, pentane, hexane, dimethyl sulfide, dimethyl
disulfide, carbon disulfide and toluene were from
Fluka, Sigma-Aldrich (Italy). All compounds were GC
grade standard with a purity higher than 99%. Labeled
8D-toluenewas purchased with a purity of 99.8% from
ARMAR Chemicals (Switzerland). All chemicals were
usedwithout any further purification.
Ultrapure water was obtained using a PureLab
Classic Pro, USF Elga instrument (Italy).
Helium 5.6 IP,medical air (hydrocarbon free, pur-
ity of 99.95%), nitrogen 5.0 IP and CO2 (5% balanced
in nitrogen) were purchased from Sol Group Spa
(Italy). Helium, medical air, nitrogen and CO2 were
purified with a super clean filter from Agilent Tech-
nologies (USA) to further remove water, oxygen and
hydrocarbon contaminants.
Nalophan bags were fabricated from a roll of Nalo-
phan tube (diameter 47 cm, film thickness 20 μm)
supplied by Kalle (Germany) according to the proce-
dure described elsewhere [29].
2.2. Preparation of standards
A liquid solution was prepared by mixing 50 μl of the
pure compounds in a 1 ml glass vial equipped with a
screw-cap mininert valve (Sigma-Aldrich, Italy). A
stock standard gaseous mixture (MIX22) was then
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obtained by introducing 20 μl of solution into a 2 l
glass flask equipped with a screw-cap mininert valve
and pre-evacuated using a vacuum membrane pump.
The internal pressure was balanced to ambient pres-
sure and the flask was then kept in a 1.1 m3 thermostat
chamber (37 °C±1 °C and RH<15%) during use.
The stock standard gaseous mixture was used for 1
month or prepared again when the amount of
subtracted volume exceeded 10% of the flask volume.
The concentrations of the mixture components are
reported in table 1.
To simulate water vapor contained in real breath
samples, humid working gaseous mixtures at about
90% RH were prepared at room conditions
(25 °C±2 °C and 50%±5% RH) flowing medical
air (500 ml min−1) through a purge and trap glass sys-
tem filled with 5 ml of fresh ultrapure water. An ali-
quot of MIX22 from the glass flask was injected into
the flow of humidified medical air during the filling of
a Nalophan bag. Tominimize water diffusion through
the Nalophan film [29], a double-walled bag having a
(film) surface-to-(sample) volume ratio (S/V ) equal
to 0.3 cm−1 was prepared by fitting one Nalophan
tube chunk inside another. This bag was equipped
with a single polypropylene septum fitting (SKC,
USA), which combines the hose/valve and the septum
holder. A long life non-stick septum (Agilent Technol-
ogies, USA)was used.
In the same way, an internal standard gaseous
stock solution containing labeled 8D-toluene was pre-
pared by evaporating 5 μl of liquid compound into a
2 l glass flask equipped with a screw-cap mininert
valve. This gaseous mixture was stored in the thermo-
static chamber and used for 1month or prepared again
when the amount of subtracted volume exceeded 10%
of the glass flask volume. The concentrations of
8D-toluene, calculated at 37 °C and ambient pressure,
was 600 ppmv.
A stock gaseous mixture with 5% CO2 was diluted
with humidified medical air at 1%, 2%, 3% and 4%
CO2 to calibrate the CO2 sensor. These mixtures were
prepared in 2 l hand-made Nalophan bags (S/V
0.3 cm−1) and kept in the thermostatic chamber for
1 d.
2.3. Needle trap device
Commercial three-bedside-hole NTDs (23-gauge
stainless-steel needle, length 60 mm), packed with
1 cm each of Divinylbenzene (80/100 mesh), Carbo-
pack X (60/80 mesh) and Carboxen 1000 (60/80
mesh) were purchased from PAS-Technology (Ger-
many) (figure 1).
Prior to first use, NTDs were conditioned in a cus-
tom-made heating device (PAS-Technology, Ger-
many) at 250 °C under a permanent nitrogen flow
(1 bar front pressure) for at least 20 h to remove impu-
rities from the sorbent materials. NTDs were then
sealed with Teflon caps and stored at room conditions
(25 °C±2 °C and RH of 50%±5%) until use. Right
before use, the NTDs were conditioned again for
30 min using the same conditions.
A plot showing the relationship between the
applied pressure different (mBar) and sampling flow
rate (mlmin–1) was obtained for each NTD by draw-
ing ambient air (25 °C±2 °C andRHof 50%±5%).
The same measurements were repeated after 20 con-
ditioning/analysis cycles to exclude possible changes
of the pressure drop through the NTD due to a rear-
rangement of sorbents or needle occlusion.
2.4. Study population
The study was carried out in the framework of
HEARTEN project (‘A co-operative mHEALTH
environment targeting adherence and management of
patients suffering from HF’, protocol number:
643694) and was approved by the Ethics Committee of
the Area Vasta Nord-Ovest (CEAVNO- Tuscany
Region). Forty patients (30 males, 10 females), hospi-
talized at the Cardio-Thoracic-Vascular Department
of the Azienda Ospedaliera-Universitaria Pisana
Table 1.Concentration ofMIX22 components calculated at
37 °Cand ambient pressure.























Figure 1.Needle trap design and sorbentmaterials used.
(DVB=divinylbenzene).
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(AOUP), were enrolled in the study after receiving
appropriate information on the whole protocol and
signing the informed consent.
2.5. Sample collection
Twenty-five milliliters of end-tidal breath samples
were collected at 15 ml min−1 from the enrolled
patients at the time of hospital admission (t0) and every
48 h until discharge (td) using a sampling device
(figure 2), made by amouthpiece (Spectra 2000, Italy),
a Capnostat 5 CO2 sensor (Respironics, Philips), an
electronic valve and three polyethylene T-piece con-
nectors. Generally, three samples were collected from
each patient during hospitalization. An aliquot (25 ml)
of ambient air was also collected at 15 ml min−1 and
analyzed to exclude contamination risks, which is a
critical problem in clinical environments [30].
Before sample collection, each subject was asked to
breathe normally through the breath sampler for
1 min to familiarize with the sampler and measure
end-tidal CO2. After setting an appropriate CO2
threshold (80%of the end-tidal CO2), a NTDwas con-
nected to the automatic system via the electronic valve
and inserted into the yellow adapter connected to the
series of polyethylene T-pieces. Based on the real-time
CO2 values, the automatedNTD sampler device (PAS-
Technology, Germany) opened the electronic valve
(delay< 50 ms) to sample end-tidal breath fraction
and accurately controlled the sampling flow rate, pres-
sure and sample volume [1]. The electronic mass-flow
meter was calibrated using amini-BUCKM-5 primary
gas flow calibrator (A. P. Buck Inc., USA) operating in
the range 1–6000 ml min−1.
The clinical data of the patients were provided
from the Cardio-Thoracic-Vascular Department of
the AOUP.
The CO2 sensor was calibrated at room conditions
(25 °C±2 °C and RH of 50%±5%) by flowing
standard working mixtures containing 1%, 2%, 3%,
4% and 5% of CO2 at 1 l min
−1. A linear relationship
between the voltage output (V) and CO2 content (%)
was observed (r> 0.998, slope of the calibration curve
1.2 V/%).
2.6. Sample analysis
Analyses were performed by a 7890B GC (Agilent
Technologies, USA) coupled to a 7010 triple quadru-
pole GC/MS (Agilent Technologies, USA) with an
electron ionization source operating at 70 eV.
The NTDs were thermally desorbed at 250 °C for
30 s in the multimode inlet, which was equipped with
a long life non-stick septum (Agilent Technologies,
USA) and an ultra-inert SPME liner (inner diameter
0.75 mm, internal volume 35 μl) (Agilent Technolo-
gies, USA). The automatic desorption was performed
using a Concept GC-Autosampler (PAS-Technology,
Germany) optimized for the fast-expansive flow
technique.
Chromatographic separation of VOCs was carried
out by a DB-5 ms ultra-inert capillary column
(60 m×0.25 mm, 1.0 μm film thickness) supplied by
Agilent Technologies (USA). The oven temperature
program was: 30 °C for 13 min, 4 °Cmin−1 to 130 °C
(3 min hold time) and 10 °Cmin−1 to 220 °C (1 min
hold time). Post run was 15 min with an oven temper-
ature of 300 °C. Helium 5.6 IP was used as the carrier
gas at 22.8 cm s−1 constant average linear velocity and
4 ml min−1 split flow.
Triple quadrupole MS detector was operated in
full scan (range set fromm/z 31 tom/z 200) and MS/
MS mode (multiple reaction monitoring, MRM).
8D-toluene (m/z of 98) was monitored using SIM
mode with a dwell time of 0.4 s. The temperature of
transfer line, ion source and quadrupoles was set at
280 °C, 280 °C and 150 °C, respectively. Helium was
used as quench gas at a flow rate of 4 ml min−1, and
nitrogen as collision gas at 1.5 ml min−1. A solvent
delay of 6 min was set to protect the filament from
water vapor. The retention times of the investigated
compounds for the applied chromatographic para-
meters as well as the quantifier ions or MRM transi-
tions used for the quantification are shown in table 2.
A deviation of±0.1 min of the expected retention
time compared to stock MIX22 and a qualifier/quan-
tifier (q/Q) ratio within 20% of the ratio measured in
stockMIX22were required for analyte identification.
The analyte concentrations were calculated in real










IS= = ´ ( )
where subscripts a indicates the analyte and IS the
internal standard, m the amount (ng) loaded into the
NTD, relative response factor (RRF), and V (ml) the
volume of breath sample collected into the NTD. The
RRFs of compounds were calculated according to the
EPA TO-15 method [31]. To determine the response
factors, an aliquot (10 μl) of 8D-toluene stock gaseous
solution was dispersed in a volume (10 ml) of dry
medical air flowing through each NTD at 5 ml min–1.
Figure 2.Breath sampler prototype composed by (a) sterile
and disposablemouthpiece, (b)CO2 sensor, (c) septum
connector, (d)needle trap device, (e) electronic valve and (f)
polyethylene T-piece connectors.
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In these conditions, each NTD was spiked with 24 ng
of 8D-toluene. Then, three working gaseous mixtures
were prepared in double-walled Nalophan bags (S/V
0.3 cm−1) by diluting (1000-, 10 000- and 100 000-
fold) theMIX22 with humidifiedmedical air. Aliquots
(25 ml) of each standard working mixture were
transferred at 15 ml min−1 into three NTDs, whose
content was determined according to the aforemen-
tioned procedure.
The instrumental detection limits (IDLs), i.e. the
analyte concentrations producing signals with a sig-
nal-to-noise ratio equal to 3, were estimated by
extracting the quantifier ions and quantifier MRM
transitions.
The data quality assurance was assessed by system-
aticallymonitoring the GC signal of 8D-toluene spiked
into NTD. A control chart was drawn reporting the
daily average ratios between the 8D-toluene peak
areas, the relevant average ratio during the whole
experimental period, the warning limits (average±1
standard deviation) and the control limits (average±2
standard deviations). In about 12 months of experi-
ments, control limits were exceeded five out of 35
times, indicating very good control of experimental
conditions. The overall variability of the internal stan-
dard signal was close to 20%.
2.7.Optimization of adsorption and desorption
parameters
The influence of desorption temperature (Tdes), deso-
rption time (tdes) and sampling flow rate (Flow) on the
NTD performances was evaluated in our experimental
conditions using a 23 full factorial design. Table 3
reports the selected experimental levels for each factor.
Five replicate experiments were performed at the
center of the experimental domain (250 °C, 30 s and
15 ml min−1), so 13 runs were randomly performed
overall. For this purpose, a gaseous working mixture
was prepared by diluting 1000-fold the MIX22 with
humidified medical air in a double-walled Nalophan
bag. Results were analyzed using the MODDE 11.0
Software (Umetrics, Sweden).
The effect of sample volume on the amount of
extracted VOCswas evaluated in triplicate at five levels
(15, 25, 50, 75 and 100 ml) and a fixed flow rate
(15 ml min−1), using a gaseous working mixture pre-
pared by a 1000-fold dilution of the MIX22 with
humidified medical air in a double-walled Nalo-
phan bag.
In addition, two NTDs were connected in series
and two aliquots (25 and 50 ml) of diluted MIX22
(1000-fold) were transferred into the NTDs to verify
that the breakthrough volume of any the analyte was
not exceeded. Due to the doubled pressure drop of two
NTDs in series, also pressure was doubled to obtain
the usualflow rate (15 ml min−1).
Furthermore, five NTDs were loaded (flow rate
15 ml min−1) with 25 ml of the previous 1000-fold
Table 2.Retention times and quantifier ions (m/z values) or transitions (Precursor ion −> Product ion) of the investigated compounds.
Collision energies (eV) are reported in brackets.





Isoprene 10.02 67 −> 41 (18 eV)
Dimethyl sulfide 10.75 62
Carbon disulfide 12.08 76
1-propanol 13.71 31
Butanal 16.71 44
2-butanone 16.92 72 −> 43 (5 eV)
Hexane 17.18 57
1-butanol 22.67 56
2-pentanone 24.39 86 −> 58 (5 eV)
Pentanal 25.28 44
Dimethyl disulfide 28.80 94 −> 79 (26 eV)
8D-toluene 30.02 98
Toluene 30.33 91 −> 39 (34 eV)
2-hexanone 31.38 100 −> 85 (1 eV)
Hexanal 32.14 56
4-heptanone 36.23 114 −> 71 (9 eV)
2-heptanone 37.13 43
Heptanal 37.85 70
Benzaldehyde 41.80 120 −> 105 (1 eV)
Table 3.Experimental levels for the investigated factors.
Factor Low level (–) High level (+)
Desorption temperature (°C) 220 280
Desorption time (s) 15 45
Sampling flow rate (ml min−1) 5 25
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diluted MIX22 to assess carry over, and then each
NTDwas analyzed two times consecutively. The deso-
rption efficiency was calculated for all the VOCs as the
ratio between the areameasured in the first desorption
(AI°) and the sum of the areas obtained in the first and
the second desorption step (AI°+AII°).
2.8. Stability studies
The stability over time of the MIX22 components was
evaluated weekly up to four weeks after the prep-
aration of the mixture in the glass flask. For this
purpose, an aliquot (50 μl) of stock gaseous MIX22
was manually injected (n=3) in the GC system to be
analyzed according to the analytical method described
in section 2.6.
The stability of MIX22 components when loaded
in the NTD was evaluated by comparing measure-
ments performed immediately after collection, after 6
and 24 h. Nine NTDs were loaded (25 ml at
15 ml min−1) with the 1000-fold diluted MIX22 and
analyzed in triplicate at each observation time accord-
ing to the method described in section 2.6. During the
experiments, NTDs were sealed with a Teflon cap and
stored at room conditions (25 °C±2 °C and RH of
50%±5%). To simulate the conditions occurring
during a typical GC sequence, the luer-lock end of the
NTD was closed with the autosampler stainless-steel
cap, whichwas equippedwith aGC septum.
2.9. Statistical analysis
Demographic and clinical data are reported as
mean±standard deviation and ranges. The distribu-
tion of variables was tested for normality by a Shapiro–
Wilk test, whereas the gender difference was evaluated
by a Mann–Whitney test. Deming regression and
analysis of variance (ANOVA) were used to evaluate
the statistical significance of the analytical method
parameters. A two-tailed p value lower than 0.05 was
considered statistically significant. Statistical analysis
and principal component analysis were performed
using GraphPad Prism v.6.0 (GraphPad, La Jolla,
USA) and XLSTAT v.2015.4.01 (Addinsoft, NewYork,
USA), respectively.
A software (G* Power, version 3.1)was used to cal-
culate the sample size assuming a level of significance
(α) of 5%, power=95% and effect size=0.51 [32].
With these values of parameters, the calculated sample
sizewas 39.
3. Results and discussion
3.1.Optimization ofMS conditions
Optimization of the tandem MS conditions was done
in a multistep process. First, 50 μl of stock gaseous
MIX22 were directly injected into the GC and a total
ion chromatogram (31<m/z<200) was acquired.
Then, analysis of the full product scan MS at different
collision energies allowed to select at least two product
ions and set up MRM transitions for each compound.
Themost abundant mass transition was selected as the
quantifier transition (Q) whereas the other was
selected as the qualifier transition (q).
Table S1 is available online at stacks.iop.org/JBR/
11/047110/mmedia in the supplementary informa-
tion reports the qualifier and quantifier transitions
with the corresponding collision energies, and the q/
Qratio.
3.2.Optimization of theNTD loading and
desorption procedure
The effect of the injection mode, e.g. split (10:1 and
5:1) and splitless, on the shape of GC signals was
investigated (figure S1). The splitless mode caused a
peak broadening that was more pronounced for more
volatile compounds such as isoprene compared to less
volatile compounds such as 2-hexanone. In fact, the
splitless mode increases the time needed to molecules
to exit the needle and reach the column and favors
diffusion. This is particularly true for more volatile
compounds, which are retained from the stronger
sorbent material (Carboxen 1000) positioned at a
higher distance from the side hole. These results led to
choose the injection split mode with a split ratio of 5:1
for VOCs desorption from the NTD and their transfer
to the chromatographic column.
Desorption temperature (x1), desorption time (x2)
and sampling flow rate (x3) were selected as the para-
meters determining the analyte peak area (y) to be
included in the 23 full factorial design. For each ana-
lyte, peak areas resulting from the experiments were
used tofit themodel:
y b b x b x b x b x x b x x
b x x b x x x ,
2
0 1 1 2 2 3 3 1,2 1 2 1,3 1 3
2,3 2 3 1,2,3 1 2 3
= + + + + +
+ +
( )
where y represents the predicted response (analyte
peak area), and xi and bi the model parameters and
coefficients, respectively.
For the majority of the compounds, desorption
temperature and sampling flow rate were themost sig-
nificant coefficients, whereas desorption time was not
important. For each compound, a refined model was
determined including only the significant terms.
Figure 3 shows an overview of the results obtained for
a representative compound (2-propanol). The plot of
replicates (figure 3(a)) shows the peak areas obtained
in the different experiments, whereas the histogram in
figure 3(b) reports the model diagnostics such as the
degree of fit (R2, explained variation) that quantifies
howwell themodel is able to reproduce the data of the
training set (experiments 1–8), and predictive power
(Q2, predicted variation) that quantifies how well the
model predicts the results of an independent set of
validation observations (experiments 9–13).
Figure 3(c) shows the values of the main model coeffi-
cients: an increased value of a parameter with a posi-
tive coefficient (e.g. time and temperature) rises the
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response, whereas the contrary is true for parameters
having negative coefficients (e.g. flow). The error bars
reflect the uncertainty on the estimate of a coefficient
and significance of the related parameter. Exper-
imental values andmodel predictions are compared in
figure 3(d).
Very VOCs showed an increased peak area (from
60% to 80%) at the higher desorption temperature,
whereas a decrease (from 10% to 30%) was observed
in less VOCs, probably due to their catalytic degrada-
tion on the surface of carbon sorbents at temperatures
close to 300 °C [33, 34].
The optimal experimental conditions for 18 out of
22 compounds (from ethanol to hexanal), calculated
from the models, were desorption temperature
280 °C, sampling flow rate 5 ml min–1 and desorption
time 30 s, whereas for the others resulted 260 °C,
5 ml min–1 and 30 s. However, the following aspects
were further considered: (a) stability of the NTD sta-
tionary phases and device reusability, (b) sampling
invasiveness and patient discomfort. Among the
three-stationary phase, DVB is the less thermally
stable: at 290 °C, its reusability is very limited, and this
increases the cost per analysis since NTDs are quite
expensive [35]. Thus, the desorption temperature was
set at 250 °C to preserve DVB from degradation and
extend the use ofNTDs up to 60 thermal cycles. Breath
sampling is considered non-invasive, but patient dis-
comfort increases very quickly when sampling is
longer than 2–3 min, especially when samples are
taken at the bedside. This sampling time represents
also a limit to avoid hyperventilation. If these sampling
times are to be respected, then aNTD loading flow rate
of at least 15 ml min−1 is required. Further tests and
analyses of real breath samples were then carried out
using a desorption temperature of 250 °C, a sampling
flow rate of 15 ml min−1 and desorption time 30 s. An
acceptable decrease of peak areas from 30% to 50%
was observed when compared to the optimal condi-
tions. Using these conditions the desorption efficiency
was higher than 95% for all compounds except carbon
disulfide, whose efficiencywas close to 90%.
3.3. Effect of sample volume onNTDefficiency
Five sample volumes (15, 25, 50, 75 and 100 ml) of
diluted MIX22 (1000-fold from stock gaseous solu-
tion) were transferred at 15 ml min−1 into each NTD
for evaluating breakthrough volume. In these condi-
tions, the total amounts of VOCs loaded into NTD
were: 200 ng (15 ml), 340 ng (25 ml), 680 ng (50 ml),
1100 ng (75 ml) and 1440 ng (100 ml), respectively.
Ethanol, acetone and carbon disulfide showed a
linear behavior up to 50 ml, whereas a deviation from
linearity was evident for dimethyl sulfide even at
25 ml. All the other compounds had a linear behavior
within the investigated range (15–100 ml), with a coef-
ficient of determination (R2) higher than 0.995. These
results were confirmed by connecting two NTDs in
series with a modified yellow adapter, so that com-
pounds not been retained in the first NTDwere adsor-
bed in the second one. Two volumes (25 and 50 ml) of
dilutedMIX22 (1000-fold from the stock gaseousmix-
ture) were transferred at 15 ml min−1 into the series
NTDs by applying a two-fold pressure, due to the
increased resistance of the system. The results con-
firmed that all the compounds, except for dimethyl
sulfide, were quantitatively collected in the first NTD
since noVOCswere found in the second one.
Figure 3.Overview of results obtained for 2-propanol: (a) plot of replicates, (b) summary offit (R2 (green),Q2 (blue), model validity
(yellow) and reproducibility (light blue)), (c)plot of coefficients and (d)model predictions. In this last plot, the correct prediction of
results from experiments 9–13, not included in themodel development, demonstrate the validity of themodel.
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3.4. Release of contaminants from sampler device
andmaterials
Five NTDs were analyzed immediately after the
conditioning step (30 min at 250 °C with a nitrogen
flow at 1 bar) to verify the effectiveness of the
conditioning procedure. Only toluene and benzalde-
hyde, probably produced by the thermal degradation
ofDVB at 250 °C,were found in all chromatograms.
The possible contamination of a breath sample
due to the contact with the sampling device (figure 2)
was excluded by analyzing humid air samples flown
through the device (results not shown).
A Nalophan bag (S/V ratio of 0.3 cm−1) was filled
with 10 l of humidified medical air and kept at room
conditions (25 °C±2 °C and RH of 50%±5%) to
evaluate the release of contaminants from Nalophan
material and the effectiveness of cleaning procedures
(the stopcock and polypropylene valve were washed
5-times with 2 ml of methanol). After 3 h, three ali-
quots (25 ml) were transferred from the bag to NTDs
at 15 ml min−1. Besides toluene and benzaldehyde,
only 2-methyl-1,3-dioxolane, a compound emitted by
recycled polyethylene terephthalate bags due to poly-
meric impurities [36], was found in these blank sam-
ples, confirming the results reported elsewhere [29].
3.5. Stability studies
The ANOVA evidenced that most compound recov-
eries from the glass flask measured right after the
preparation and after a 6 d storagewere not statistically
significant different (p<0.05). Only aldehydes (i.e.
butanal, pentanal, hexanal, heptanal and benzalde-
hyde) showed a marked decrease (about 20%–50%)
after 6 d, probably due to spontaneous reactions with
oxygen to produce carboxylic acids [37]. The occur-
rence of such reactions was confirmed by the presence
in the extracted ion chromatogram of the signal
corresponding to an m/z ratio of 60, resulting from
the McLafferty rearrangement typical of carboxylic
acids. A good correlation (r=0.80, p<0.05) was
found between the peak areas of aldehydes and the
corresponding carboxylic acids. After 1 month, alco-
hols and ketones showed recoveries ranging between
70% and 90%, whereas dimethyl sulfide decreased at
about 50%.
In the case of the double-walled Nalophan bag
(S/V=0.3 cm−1), no significant variations
(p<0.05) were observed within 3 h in the content of
water and for the majority of the investigated com-
pounds (1000-fold dilution in humid conditions),
confirming the results reported elsewhere [29]. In fact,
only carbon disulfide and aldehydes showed a loss of
15% and 20%within 3 h, respectively. For this reason,
we suggest to transfer samples into NTDs as soon as
possible.
All analytes were stable in NTDs for 24 h, except
for ethanol, 2-propanol and acetone, which showed a
decrease of about 20%. The recovery of dimethyl
sulfide and carbon disulfide was lower than 60%. No
improvement was observed by sealing the luer-lock
end of NTDs with autosampler stainless-steel caps
instead of Teflon caps.
3.6. IDLs andRRFs
The IDLs, i.e. the minimum analyte concentrations
producing a signal distinguishable from noise within a
statistical confidence limit (i.e. a signal-to-noise ratio
equal to 3), were estimated by extracting the quantifier
ions from the TIC chromatogram and/or using
quantifierMRM transitions.
Table S2 in the supplementary information report
the RRFs and IDLs for all the investigated compounds.
The IDLs resulting from the extraction analyses were
lower than 500 pptv for all compounds, except for
ethanol (3 ppbv), C4-C7 aldehydes (1 ppbv) and C3-
C4 alcohols (1 ppbv), whereas the IDLs from MRM
analyses were always below 200 pptv, and was close to
20 pptv for dimethyl sulfide. The pre-concentration
factors, calculated from the ratios of peak areas
obtained by themanual injection of theMIX22 (50 μl)
and NTD desorption, ranged between 500 and 2000.
Inter- and intra-day relative standard deviations of the
RRFs were always below 15% for all analytes except for
carbon disulfide (25%), confirming NTME as a reli-
able method for the quantification of VOCs in human
breath.
3.7. Application to real samples:HFpatients
The optimized NTME procedure was applied to
monitor the chemical composition of breath samples
collected from forty patients suffering from HF.
During the collection time, the self-paced respiratory
rate was constant and the real-time end-tidal CO2
partial pressures fluctuated randomly within a 10%.
The simplicity (and very low pressure drop) of the
sampling device and the short sampling time (i.e.
<3 min) avoided the hyperventilation observed by
other authors [37]. The constant respiratory rate also
allowed to exclude modifications of breath composi-
tion due to changes of this parameter [38, 39].
Table 4 reports the demographic and clinical data
of patients at the first observation time (hospital
admission).
TheMann–Whitney test did not reveal statistically
significant gender differences for any of the above car-
diorespiratory variables as well as for blood sample
values, whereas weight and body mass index were sig-
nificantly different (p<0.05). Moreover, glycaemia
and glycated hemoglobin were not statistically differ-
ent between diabetic and non-diabetic
patients (p>0.05).
All exhaled breath samples contained hydro-
carbons (e.g. pentane and isoprene), carbonyl com-
pounds (e.g. acetone, 2-butanone and 2-pentanone),
alcohols (e.g. ethanol, 2-propanol and 1-butanol) as
well as other compounds (e.g. 1-propanol). Aldehydes
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(e.g. hexanal and heptanal) and dimethyl sulfide were
detected only occasionally and therefore were not
included in the data preliminary evaluation. The etha-
nol and 2-propanol concentrations in breath ranged
between 40–2200 ppbv and 3–800 ppbv, respectively.
These values were comparable with those measured in
the ambient air, confirming the exogenous origin of
these compounds, which are generally contained in
the disinfectants used in hospitals [30].
Over 90% of patients had underlying comorbid-
ities, including diabetes mellitus (n=15), hyperten-
sion (n=29), dyslipidemia (n=22), chronic
obstructive pulmonary disease (n=8), chronic kid-
ney disease (n=12), chronic liver disease (n=2),
coronary artery disease (n=18), atrial fibrillation
(n=13), and oncological diseases (n=6).
Principal component analysis was used to obtain
an overall view of the internal structure of the dataset
(figure 4), including the data from clinical analyses and
the chemical characterization of exhaled breath at the
first observation time (t0).
The loading plot (figure 4(a)) shows that the con-
centration of BNP, a commonly accepted biomarker
for the diagnosis andmonitoring of HF [16], was posi-
tively correlated with acetone (r=0.51, p<0.05)
and creatinine (r=0.62, p<0.05) and negatively
correlated with oxygen saturation (r=−0.48,
p<0.05), isoprene (r=−0.36, p<0.05) and esti-
mated glomerular filtration rate (r=−0.36,
p<0.05). In addition, low levels of left ventricular
ejection fraction (LVEF) were related to high levels of
BNP (r=−0.44, p<0.05), acetone (r=−0.38,
p<0.05) and 2-pentanone (r=−0.37, p<0.05).
These data are consistent with the acute conditions
and the disease severity degree of most patients, whose
majority (60%) belonged to NYHA class III (n=17)
and IV (n=7). The low LVEF and oxygen saturation
document that patients’ hearts were unable to perform
their function correctly and that respiration was ham-
pered. In some patients, disease manifestations, such
as the reduction of cardiac output and the presence of
different amounts of water in the lungs (up to pul-
monary edema), induce a progressive impaired perfu-
sion of other organs and apparatus. This condition,
sometimes associated to comorbidities, produces a
failure of other functions like renal and/or liver. As an
example, the reduced estimated glomerular filtration
rate and the high creatinine levels suggest a poor kid-
ney function in some patients of this study. In the HF
syndrome, there are changes of metabolic and neu-
roendocrine responses with a cardiac release of
natriuretic peptides like BNP and an increase of
heart rate.
The possible enhancement of lipolysis could trig-
ger the increase of circulating free fatty acids [40] and
induce an overproduction of ketone bodies (i.e. acet-
oacetate, beta-hydroxybutyrate and acetone). Ketone
bodies are the most efficient substrate to produce ade-
nosine triphosphate and therefore could be a particu-
larly useful energy source when the oxygen delivery to
tissues is reduced, such as in acute HF [41]. The
impaired metabolism was discussed by Lommi et al
[42], who hypothesized that free fatty acids could be an
alternative source of energy for the heart during acute
HF. On the other hand, ketone bodies are also pro-
duced in different conditions, e.g. unbalanced diabetes
mellitus or fasting [43], making the relationship of
breath acetone with HF less clear. In our study, the
possible interference from fasting was partially
reduced by collecting breath samples always in the
morning at the same time, 2 h after breakfast. The
non-statistically different average values for blood gly-
caemia and glycated hemoglobin between diabetic and
non-diabetic patients suggest that diabetes was under
control formost patients.
Table 4.Characteristics of enrolled patients (n=40) at thefirst
observation time. Data are shown asmean±standard deviation
(range).
Characteristics HF patients (n=40)
Age (years) 70±10 (42–85)
Gender,male:female 30:10
Weight (g) male: 80±14 (60–123)
female: 63±8 (51–75)







Systolic blood pressure (mmHg) 122±20 (90–180)
Diastolic blood pressure (mmHg) 74±14 (50–110)
Heart rate (bpm) 75±18 (53–150)
Respiratory rate (breaths per
minute)
19±7 (8–39)
Left ventricular ejection frac-
tion (%)
33±12 (15–65)
Low-density lipoprotein (mg dl−1) 98±38 (42–182)
High-density lipoprotein (mg dl−1) 43±12 (26–77)
Triglyceride (mg dl−1) 105±43 (43–274)
Calcium (mg dl−1) 9±1 (7–10)
Sodium (mg dl−1) 140±7 (105–146)
Potassium (mg dl−1) 4±1 (1–5)
Blood creatinine (mg dl−1) 1.3±0.5 (0.8–3.3)
Estimated glomerular filtration rate
(ml min−1)
55±20 (19–104)
Blood brain natriuretic peptide
(pg ml−1)
1230±970 (140–3500)
Oxygen saturation (%) 95±4 (79–99)
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Furthermore, median (interquartile range) breath
acetone concentrations at the admission calculated for
diabetic (n=15) and non-diabetic subgroup
(n=25) [1200 ppbv (800–1700 ppbv) and 1160 ppbv
(700–2600 ppbv), respectively] were not significantly
different (p>0.05). We hypothesized that breath
acetone levels in our HF patients could be related to
cardiac decompensation more than to other factors
(i.e. diabetes and fasting). Moreover, in the literature a
relationship between BNP and acetone has been pre-
viously described [44, 45]. A good correlation
(r=0.77, p<0.001) between these two analytes was
found in 59 HF patients in acute conditions [44], and
high acetone levels (3.7 μg l−1, 50th percentile) in
exhaled breath were associated to poor prognosis in
HFpatients showing a reduced ejection fraction [45].
In our case, only BNP values in blood samples,
LVEF measurements and 2-pentanone in exhaled
breath were significantly different among patients
belonging to different NYHA functional classes. In
fact, the median (interquartile range) concentration of
BNP was 350 pg ml−1 (300–760 pg ml−1) among
patients in class I (n=4), 560 pg ml−1
(250–1100 pg ml−1) in class II (n=12), 1250 pg ml−1
(700–2100 pg ml−1) in class III (n=17) and
2100 pg ml−1 (800–3100 pg ml−1) in class IV (n=7).
The LVEF was 45% (35%–55%) for patients in class I,
35% (30%–40%) in class II, 30% (20%–40%) in class
III and 25% (20%–30%) in class IV. The concentra-
tion of 2-pentanone in exhaled breath was 110 pptv
(80–250 pptv) among patients in class I, 360 pptv
(190–580 pptv) in class II, 370 pptv (200–1000 pptv)
in class III and 850 pptv (500–1100 pptv) in class IV.
Slightly higher breath acetone concentrations, even if
not significant (p>0.05), were also observed in
higher NYHA classes: NYHA I had a median of
900 ppbv and an interquartile range 700–1000 ppbv,
whereas NYHA IV had a median of 1600 ppbv and an
interquartile range 1200–2600 ppbv. On the contrary,
the corresponding values of exhaled breath isoprene
slightly decreased from 450 ppbv (280–570 ppbv) to
160 ppbv (100–400 ppbv). The score plot (figure 4(b))
shows that patients belonging to different NYHA
functional classes are not separated, as the large inter-
subject variability of clinical and breath data could
hide other possible differences, as discussed for acet-
one from other authors [46]. For these reasons, we
postulate that patient’s monitoring by breath analysis
would be more successful if performed in single sub-
jects over time, as we already reported for breath mea-
surements in general terms [10]. In this way, each
patient would act as his/her own control and varia-
tions of breath composition could be correlated more
easily to the disease evolution [47].
Figure 5 shows the variations over time of end-
tidal CO2 partial pressure and breath concentration of
acetone, isoprene, 2-pentanone and blood BNP levels
normalized to values measured at the admission (t0)
for two representative patients (P_9 and P_13).
In our population, isoprene showed different pat-
terns. In fact, about 40% of patients showed a 40%
decrease of breath isoprene concentration between
admission and discharge from the hospital, whereas
30% showed an isoprene increase of about 50%. No
difference in isoprene concentration was observed
between the correspondent breath samples collected
from the remaining patients (30%). Due to the low
affinity with blood and the fast diffusion of isoprene
through alveolar capillaries, the increase may be rela-
ted to an improved hemodynamic condition, as
recently pointed out by others [48, 49]. In addition, the
combination of a reduced sterol synthesis and a
reduced pool of squalene peroxidation by free radicals
could also be the reason of the isoprene lower
Figure 4.Principal component analysis of the patients’ dataset (n=40) at t0: loading plot (a) and score plot (b). Legend: high-density
lipoprotein (HDL), low-density lipoprotein (LDL), left ventricular ejection fraction (LVEF), oxygen saturation (SpO2), heart rate
(HR), respiratory rate (RR), estimated glomerular filtration rate (eGFR), end-tidal CO2 (ETCO2), brain natriuretic peptide (BNP),
calcium (Ca), potassium (K), sodium (Na), glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure
(DBP). Black up-pointing triangle (NYHA I), red dots (NYHA II), blue circle (NYHA III) and green diamond (NYHA IV).
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concentration observed in the acute phase [50]. Also
for pentane and 1-butanol, no similar trends in differ-
ent patients were found. These data confirmed that
one or more confounding factors (e.g. diet and drug
therapy) could increase the complexity with a real
difficulty for the meaning of these breath compounds
inHF [51].
Relatively to breath concentrations of 2-butanone
and 2-pentanone, in about 75% of patients, there is a
decrease of approximately 40% and 60% from the
admission to the discharge, respectively. These
Figure 5.Acetone, isoprene and 2-pentanone breath concentrations, end-tidal CO2 partial pressure andBNP blood concentrations
measured over time.Datawere normalized to the valuesmeasured at thefirst sample collected at the admission frompatients P_9 and
P_13. Error bars indicate the standard deviation.
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substances could derive by fatty acids degradation
[52], which is presumably related to the increased lipo-
lysis occurring during acuteHF [42].
Table 5 reports the breath acetone concentrations
measured in all the enrolled patients (n=40) at the
admission, after 48 h time spans (when available) and
at the discharge.
The majority of HF patients (n=31) showed a
remarkable decrease of breath acetone concentration
over time (a factor 3 at least) as their health conditions
improved. Among these, the subgroup of nine patients
characterized by the lowest LVEF values (<20%) and
highest BNP blood levels (>1000 pg ml−1) at the
admission exhibited the most pronounced decreases
(a factor of 6 or higher, up to a factor of 80 in the case
of patient P_23). As mentioned above, this behavior
could be related to an altered oxidation of fatty acids
during the acute phase leading to an increased produc-
tion of ketone bodies such as acetone [41, 42]. Only
nine HF patients, namely P_11, P_15, P_18, P_22,
P_25, P_26, P_29, P_35 and P_39, did not display any
decrease of the breath acetone levels between admis-
sion and discharge. These nine patients, belonging to
NYHA class I and II, showed the classical symptoms of
HF (e.g. dyspnea) at the admission and maintained a
low level of BNP (<500 pg ml−1) during all the hospi-
talization time.
Interestingly, patients suffering fromboth diabetes
and HF displayed the same decreasing trend of breath
acetone and, from this point of view, they were indis-
tinguishable from the other patients. Even if breath
acetone can change for a variety of reasons, our find-
ings suggest that the evolution of theHF conditionwas
the leading factor explaining the observed variations in
the enrolled population.
4. Conclusions
This paper reports a validated analytical procedure for
the determination of VOCs (e.g. ketones, aldehydes,
alcohols, hydrocarbons, sulfur and aromatic com-
pounds) in exhaled breath samples byNTME followed
by GC-MS/MS analysis. The analytical protocol was
optimized using humidified gaseous standard mix-
tures to accurately simulate the performance of the
technique with real breath samples. The use of
experimental design allowed us to clarify the role of
the sampling flow rate onNTD efficiency in extracting
VOCs frombreath samples.
An aliquot (25 ml) of sample was loaded into the
NTD at 15 ml min−1, and the analytes were thermally
desorbed at 250 °C for 30 s using a split ratio of 5:1.
These conditions, that guarantee a quantitative deso-
rption from the three-bed NTD without the occur-
rence of carry over effects, represent in our opinion the
best compromise between optimum performance,
cost of measurement (extended NTD life time) and
reduced discomfort to patients.
The method was successfully applied to monitor
the chemical composition of breath samples collected
from forty patients suffering from HF. Our results
highlighted the potential role of breath acetone for
monitoring the health conditions of these patients, as a
remarkable decrease (at least to a factor of 3) of acet-
one concentration was observed for the majority
patients at the discharge compared to admission time.
The results obtained during this study strongly
support the hypothesis that the acetone concentration
in breath increases when the patient is at home and
health conditions worsen for a HF relapse. Thus, the
use of point of care devices equipped with a reliable
sensor system for monitoring acetone in breath may
be useful to reveal a possible HF exacerbation event, as
Table 5.Breath acetone concentration (ppbv)measured for all the
enrolled patients (n=40) during the hospitalization: at the
admission (t0), after 48 h time spans (t1, t2 and t3) and at the
discharge (td).
Collection points
ID patient t0 t1 t2 t3 td
P_1 1200 430 500
P_2 930 620 240
P_3 880 500 260
P_4 1580 750 710
P_5 1140 580 500
P_6 1840 340 300
P_7 1050 600 320
P_8 1750 820 570
P_9 3650 310 230 420 170
P_10 1560 490 500
P_11 300 110 260
P_12 2620 1770 1670
P_13 710 220 170 120
P_14 1000 310 350
P_15 1610 1140 680 1240
P_16 1000 740 760
P_17 3420 1640 1070 620 400
P_18 400 610 390
P_19 2250 1010 810
P_20 700 660 540 380
P_21 4530 4200 2680 1290
P_22 470 310 330
P_23 27520 5920 4620 880 380
P_24 1030 1060 470 360
P_25 330 330 380 420 330
P_26 790 510 630 770 820
P_27 1710 360 590 460 240
P_28 3720 330 240
P_29 590 1540 420
P_30 6440 1020 600
P_31 4360 770 540 370 320
P_32 600 240 520 250
P_33 1220 520 140 340
P_34 3560 2720 350
P_35 1160 1490 3210 1080
P_36 600 400 430
P_37 260 110 140
P_38 1710 270 230
P_39 210 200 230
P_40 6040 15890 300
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they might provide an early advice to the patients and
the family doctors.
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